Fluticasone Propionate + Formoterol

Not Applicable

08/02/2023 Inhaled corticosteroids with long-acting beta₂ agonists for treating asthma>

[R] The Ministry of Health’s Drug Advisory Committee has recommended the following inhaled corticosteroid/long-acting beta₂ agonist (ICS/LABA) inhalers for inclusion on the MOH Standard Drug List (SDL) for treating asthma in view of acceptable clinical and cost-effectiveness:

• Fluticasone furoate/vilanterol (Relvar Ellipta) 100/25 mcg (30 inhalations) and 200/25 mcg (30 inhalations) inhalation powder;

• Budesonide/formoterol (DuoResp Spiromax) 160/4.5 mcg (120 inhalations) and 320/9 mcg (60 inhalations) inhalation powder.

[R] The Committee has also recommended the following ICS/LABA inhalers for retention on the MOH SDL, in view of acceptable proposals from the companies:

• Fluticasone propionate/salmeterol (Seretide Accuhaler) 100/50 mcg (60 inhalations), 250/50 mcg (60 inhalations), 500/50 mcg (60 inhalations) inhalation powder;

• Fluticasone propionate/salmeterol (Seretide Evohaler) 50/25 mcg (120 inhalations), 125/25 mcg (120 inhalations), 250/25 mcg (120 inhalations) inhalation aerosol;

• Budesonide/formoterol (Symbicort Turbuhaler) 160/4.5 mcg (120 inhalations) inhalation powder;

• Budesonide/formoterol (Symbicort Rapihaler) 80/2.25 mcg (120 inhalations), 160/4.5 mcg (120 inhalations) inhalation aerosol.

[NR] Of note, Symbicort Turbuhaler 80/4.5 mcg, 320/9 mcg and Symbicort Rapihaler 80/4.5 mcg will be delisted with effect from 1 August 2023 due to discontinuation by the company.

The subsidy class and subsidy implementation dates (if applicable) for all ICS/LABA inhalers are provided in the Annex.

Legend

This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration